These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 37997745)
1. Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis. Tsiogkas SG; Karamitrou EK; Grammatikopoulou MG; Zafiriou E; Bogdanos DP Curr Med Res Opin; 2024 Feb; 40(2):155-163. PubMed ID: 37997745 [TBL] [Abstract][Full Text] [Related]
2. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis. Blauvelt A; Rich P; Sofen H; Strober B; Merola JF; Lebwohl M; Morita A; Szepietowski JC; Lambert J; Hippeli L; Colston E; Balagula E; Banerjee S; Thaçi D J Am Acad Dermatol; 2024 Apr; 90(4):775-782. PubMed ID: 38122848 [TBL] [Abstract][Full Text] [Related]
3. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis. Xu Y; Li Z; Wu S; Guo L; Jiang X Front Immunol; 2023; 14():1180170. PubMed ID: 37334353 [TBL] [Abstract][Full Text] [Related]
4. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542 [TBL] [Abstract][Full Text] [Related]
6. Deucravacitinib for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Toth OAS; Meldola PF; Machado PG; Chiarelli GFC; Schnorrenberger E; Kracik JLS; de Carvalho CC; Guzatti JVL; Mease PJ J Drugs Dermatol; 2024 Feb; 23(2):67-73. PubMed ID: 38306122 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942 [TBL] [Abstract][Full Text] [Related]
8. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA J Am Acad Dermatol; 2023 Jan; 88(1):40-51. PubMed ID: 36115523 [TBL] [Abstract][Full Text] [Related]
9. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis. Truong TM; Pathak GN; Singal A; Taranto V; Rao BK Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials. Kang Q; Chen JS; Yang H Front Immunol; 2022; 13():1021537. PubMed ID: 36300119 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: A systematic review and meta-analysis. Aljefri YE; Ghaddaf AA; Alkhunani TA; Alkhamisi TA; Alahmadi RA; Alamri AM; Alraddadi AA Dermatol Ther; 2022 Jul; 35(7):e15544. PubMed ID: 35499185 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. Qiu J; Liu J; Liu W; Lin F; Shi N Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017 [TBL] [Abstract][Full Text] [Related]
16. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Gooderham MJ; Hong HC; Litvinov IV Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692 [TBL] [Abstract][Full Text] [Related]
18. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A J Am Acad Dermatol; 2023 Jan; 88(1):29-39. PubMed ID: 35820547 [TBL] [Abstract][Full Text] [Related]
19. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481 [TBL] [Abstract][Full Text] [Related]
20. Deucravacitinib for the Treatment of Psoriatic Disease. Lé AM; Puig L; Torres T Am J Clin Dermatol; 2022 Nov; 23(6):813-822. PubMed ID: 35960487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]